CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 6 enrolled
Drug / intervention
[14C]-MD1003drug
Likely dose
[14C]-MD1003 100mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04223232
NCT04223232Phase 1Completed
CompareCT.gov

An Open-Label, Single-Dose, Single-Period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-MD1003 in Healthy Male Subjects

MedDay Pharmaceuticals SA·interventional·Posted Jan 10, 2020·Updated Nov 2, 2020

In Brief

A Phase 1 clinical trial evaluating [14C]-MD1003 for Healthy Volunteers. Completed, enrolled 6 participants across 1 site.

Detailed Summary

This single-center, open-label, non randomized Phase I study is being conducted to investigate the pharmacokinetics, mass balance and metabolite profiling and identification after a single oral dose of 100mg of \[14C\]-MD1003 in 6 healthy males subjects. The radioactivity will be followed in the blood, urine and faeces to study MD1003 metabolism.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy Volunteers
CountriesUnited Kingdom
CollaboratorsQuotient Sciences

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 10, 2020
Enrollment StartDec 10, 2019
Primary CompletionJan 22, 2020
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 6.5 years ago

Interventions

[14C]-MD1003drug

single oral dose of 100mg \[14C\]-MD1003